Published on 21/12/2025
Step-by-Step Comparison of UK Clinical Trial Application Timelines with the EU
Timelines for clinical trial applications are a critical factor in sponsor decision-making, influencing where global studies are initiated. In the United Kingdom (UK), the process is governed by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA), using the Integrated Research Application System (IRAS). In the European Union (EU), timelines are harmonised under the EU Clinical Trials Regulation (CTR 536/2014) through the Clinical Trials Information System (CTIS). Post-Brexit, the UK is no longer part of the EU system, creating differences sponsors must understand for efficient trial planning.
This article offers a step-by-step tutorial comparing UK and EU timelines for clinical trial applications, highlighting regulatory frameworks, procedural steps, and strategies to accelerate approvals.
Background and Regulatory Framework
UK Regulatory System
Applications are submitted via IRAS to MHRA and HRA. The MHRA evaluates safety and quality, while HRA/Research Ethics Committees (RECs) assess ethical and governance aspects.
EU CTR Framework
In the EU, applications are filed via CTIS under CTR 536/2014. One dossier covers all Member States, with coordinated review timelines binding across the EU.
Global Harmonisation
Both systems are aligned with ICH E6(R2), ensuring data from
Core Clinical Trial Insights — Step-by-Step Timeline Comparison
Step 1 — Application Preparation
UK: Applications are prepared in IRAS, requiring IMPD, protocol, IB, and insurance documents.
EU: CTIS requires a harmonised dossier with Module 1 (local) and Module 2 (scientific/technical). Preparation time depends on trial complexity.
Step 2 — Submission
UK: Applications are submitted simultaneously to MHRA and HRA via IRAS.
EU: Single submission via CTIS with RMS (Reporting Member State) coordinating review.
Step 3 — Validation
UK: MHRA validates applications within 14 days.
EU: Validation in CTIS takes up to 10 days, extendable by 5 days for queries.
Step 4 — Assessment
UK: Standard review timeline is 30 days, with possible extension for complex ATMPs or questions.
EU: Part I assessment (scientific) takes 26 days, followed by Part II (ethics/national aspects) in 45 days, with an optional extension of 31 days for complex studies.
Step 5 — Ethics Review
UK: Conducted by HRA/RECs in parallel with MHRA review, typically within 60 days.
EU: Ethics review is included in Part II timelines coordinated across Member States.
Step 6 — Approval Timelines
UK: Combined MHRA/HRA approvals are usually granted within 60 days, with fast-track routes available for urgent COVID-19 or public health trials.
EU: Approval timelines under CTR can extend to ~106 days for complex multi-country studies.
Step 7 — Appeals and Queries
Both systems allow sponsors to respond to questions during review. Response times can extend the overall timeline if queries are significant.
Step 8 — Post-Approval Amendments
UK: Substantial amendments are submitted via IRAS, typically reviewed within 35 days.
EU: Amendments are filed in CTIS, with timelines varying depending on scope and Member State.
Best Practices & Preventive Measures
- Prepare high-quality, complete dossiers to avoid validation delays.
- Engage with MHRA scientific advice or EMA parallel consultation early for complex trials.
- Plan for extended timelines in EU multi-country studies under CTR.
- Use fast-track routes in the UK for urgent public health or pandemic-related trials.
- Monitor timelines closely to ensure alignment with global development plans.
Scientific and Regulatory Evidence
- Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
- MHRA Guidance on CTA Applications
- EU Clinical Trials Regulation (CTR 536/2014)
- ICH E6(R2) – Good Clinical Practice
- HRA IRAS Guidance
Special Considerations
- Oncology Trials: Expedited in both UK and EU due to public health significance.
- Rare Disease Trials: Timelines may be prioritised due to limited patient populations.
- Advanced Therapies: ATMPs often require extended review periods in both systems.
- Pediatric Trials: UK and EU require additional safeguards, potentially lengthening approvals.
When Sponsors Should Seek Regulatory Advice
- When timelines are critical for global submissions.
- If planning adaptive or decentralised trial designs.
- For ATMPs, rare disease, or pediatric studies requiring additional scrutiny.
- When parallel UK/EU filings are necessary.
- If facing repeated delays in validation or ethics review.
FAQs
1. How long does MHRA take to approve a CTA?
Typically 30 days for review, with full MHRA/HRA approval granted within ~60 days.
2. What is the EU CTR timeline for approvals?
CTR sets coordinated timelines of up to 106 days for complex multi-country studies.
3. Does Brexit affect UK timelines?
Yes. The UK now operates separately from CTIS, but maintains similar ~60-day timelines.
4. Are fast-track approvals available in the UK?
Yes. MHRA offers expedited routes for COVID-19, urgent public health, and priority trials.
5. How are amendments handled?
In the UK, via IRAS with ~35-day review; in the EU, via CTIS with varying timelines.
6. Which system is faster—UK or EU?
The UK is generally faster (~60 days) compared to EU CTR (~106 days for complex trials).
7. Can sponsors align UK and EU timelines?
Yes, by planning submissions in parallel and engaging early with regulators.
Conclusion
UK and EU trial application timelines differ post-Brexit but remain broadly harmonised with ICH standards. The UK offers a ~60-day approval window via MHRA/HRA, while EU CTR processes can extend beyond 100 days for multi-country trials. Sponsors should prepare robust dossiers, leverage fast-track options, and seek regulatory advice early to minimise delays and align global development plans.